Saturday, 20 June 2026
  
Login

Australia's most trusted
source of pharma news

Saturday, 20 June 2026
News

10 arrivals bump Review List to 46

Posted 16 June 2026 AM

The number of 'new medicines' currently under evaluation in Australia has jumped to 46 after the TGA accepted an additional 10 type A applications.

Among the newcomers is AstraZeneca’s hard-to-control hypertension drug baxdrostat – one of the company’s blockbuster hopefuls to deliver US$80 billion in total revenue by 2030.

To see the whole article, please login

Popular

Aussie book tackles pharma burnout
New Aussie Country Leader named
Novartis boss surprise resignation
Will evolutionary drug be funded?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (4)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home